Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events

Story continues below

Item 8.01Other Events

As previously disclosed in a Current Report on Form 8-K filed on
December 19, 2016, Interpace Diagnostics Group, Inc. (the
Company) announced a registered direct public offering of
2,000,000 shares of the Companys common stock, par value $0.01
per share (the Common Stock), at a price of $0.53 per share and
prefunded warrants to purchase 1,600,000 shares of Common Stock
(the Registered Direct Offering). A copy of the legal opinion of
Pepper Hamilton LLP relating to the legality of the issuance and
sale of the shares of Common Stock, warrants and shares of Common
Stock issuable upon exercise of the warrants in the Registered
Direct Offering is filed herewith as Exhibit 5.1.

The closing of the Registered Direct Offering is expected to take
place on December 22, 2016, subject to customary closing
conditions.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking
statements. Forward-looking statements include, but are not
limited to, statements that express
the Companys
intentions, beliefs, expectations, strategies, predictions or
any other statements related to
the Companys
future activities, or future events or conditions. These
statements are based on current expectations, estimates and
projections about
the Companys business based,
in part, on assumptions made by management. These statements are
not guarantees of future performances and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including those risks discussed in

the Companys Annual Report on Form 10-K and in other
documents that
the Company files
from time to time with the U.S. Securities and
Exchange
Commission. Any forward-looking statements
speak only as of the date on which they are made, and

the Company does not undertake any
obligation to update any forward-looking statement to reflect
events or circumstances after the date of this report, except as
required by law.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

Exhibit Number

Description

5.1

Opinion of Pepper Hamilton LLP

23.1

Consent of Pepper Hamilton LLP (included in Exhibit 5.1)


About Interpace Diagnostics Group (NASDAQ:IDXG)


An ad to help with our costs